IXICO has released the tenth version of its AI-powered IXI neuroimaging platform, enhancing processing speed, data capacity, and image analysis accuracy. The platform supports pharmaceutical companies in developing drugs for neurological diseases like Alzheimer's and Parkinson's by analyzing clinical trial imaging data with advanced machine learning. Version 10 adds remote image access and data quality checks, enabling faster handling of larger datasets. This upgrade also supports IXICO's TechBio strategy to expand market reach through licensing and partnerships, aiming to help biopharma make earlier, better-informed decisions in drug development.
Distribution Solutions Group (DSGR) agreed to be acquired by LKCM Headwater Investments for $35 per share in cash, taking the company private. The deal fixes the stock price at $35, prompting analyst Stephens to downgrade DSGR to "Equal Weight" with ...
U.S. Bancorp reported strong Q2 2026 results with earnings per share of $1.35 and record revenues of $7.71 billion, both surpassing analyst expectations. The growth was driven by increased lending activity and higher net interest income. Following th...
T3 Defense Inc. will execute a 1-for-125 reverse stock split on July 20, 2026, combining every 125 shares into one to increase its share price. This move aims to raise the stock price from its current low of $0.05 per share and comply with NASDAQ lis...
General Electric, now operating as GE Aerospace, reported strong Q2 2026 earnings with EPS of $2.02 and revenue of $13.35 billion, both exceeding analyst expectations. The company's growth was driven by high demand in its commercial aerospace service...
Heilind Electronics announced the availability of the Brady i4311 Industrial Label Printer, a portable, cordless printer that combines benchtop-quality wide-format printing with all-day battery life and ergonomic design. Weighing 13 lbs and capable o...
